Pharvaris NVFRA:9EN -1.76%28 EV-to-FCF is -12.91 as of Jul. 11, 2026. GuruFocus rates FRA:9EN with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 330 Biotechnology companies, Pharvaris NV ranks worse than 303030% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharvaris NV's Enterprise Value is €1,902.70 Mil.
Pharvaris NV's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-147.42 Mil. Therefore, Pharvaris NV's EV-to-FCF for today is -12.91.
The historical rank and industry rank for Pharvaris NV's EV-to-FCF or its related term are showing as below:
FRA:9EN'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.01 Med: 0 Max: 0
Current: -13.01
FRA:9EN's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs FRA:9EN: -13.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharvaris NV's PE Ratio (TTM) for today is calculated as:
Pharvaris NV's share price for today is €30.70.
Pharvaris NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.739.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pharvaris NV EV-to-FCF Related Terms
Pharvaris NV EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pharvaris NV's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharvaris NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharvaris NV EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharvaris NV's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pharvaris NV's EV-to-FCF falls into.
Pharvaris NV's current Enterprise Value is €1,902.70 Mil.
Pharvaris NV's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-147.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharvaris NV (FRA:9EN) has a EV-to-FCF of -12.91 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pharvaris NV and its competitors. According to the industry distribution chart, Pharvaris NV ranks #999999 out of 330 companies in the Biotechnology industry.
Is Pharvaris NV's EV-to-FCF too high?
Pharvaris NV's current EV-to-FCF is -12.91. Based on the distribution chart, Pharvaris NV ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharvaris NV has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's EV-to-FCF compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #999999 out of 330 companies for EV-to-FCF. This places Pharvaris NV in the lower half of its industry. The industry median EV-to-FCF is 16.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pharvaris NV and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharvaris NV's current EV-to-FCF is -12.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (FRA:9EN) has a current EV-to-FCF of -12.91. The current EV-to-FCF is -12.91. Pharvaris NV's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pharvaris NV (FRA:9EN), the current EV-to-FCF is -12.91 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
28GF Score
Get the complete analysis for FRA:9EN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9EN has been successfully added to your 
